The Oncologist
9 CD8+ T Cells and Clinical Outcomes from the CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition (Cyto-KIK) Trial
Abstract Background In 2020, CheckMate9ER established cabozantinib (cabo) and nivolumab (nivo) as a first-line treatment regimen for metastatic clear cell renal cell carcinoma (mccRCC). Despite recent therapeutic advancements in mccRCC, only about 10-15% of patients will achieve a complete response (CR) to current first-line therapy. Improved outcomes with neoadjuvant compared to adjuvant immune checkpoint inhibitors has been demonstrated in several tumor types including non-small cell lung cancer and melanoma. Cyt …